Skip to main content
Explore URMC

menu

Pancreatic Cancer: PEGylated Recombinant Human Hyaluronidase in Combo With Nab-Paclitaxel + Gemcitabine VS. Placebo + Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Research Question:
How safe and how well tolerated is the study drug PEGPH20 compared with placebo when used in combination with nab-paclitaxel and gemcitabine?

Basic Study Information

Purpose:
PEGPH20 is an enzyme that breaks down a specific tissue component called hyaluronan (HA) produced by some tumors. Currently PEGPH20 is experimental and is being tested in patients with pancreatic and lung cancers.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02715804?term=HALO-109-301&rank=1
Study Reference #: IGIP-16006

Lead Researcher (Principal Investigator)

Lead Researcher: Marcus Noel

Study Contact Information

Study Coordinator: Kari Steinmetz
Phone: (585) 276-4447
Email: Kari_Steinmetz@urmc.rochester.edu

Additional Study Details

Return to Search